<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304131</url>
  </required_header>
  <id_info>
    <org_study_id>Earlytect</org_study_id>
    <nct_id>NCT04304131</nct_id>
  </id_info>
  <brief_title>Colorectal Cancer Screening Using Stool DNA-based SDC2 Methylation Test: a Pilot Study</brief_title>
  <official_title>Colorectal Cancer Screening Using Stool DNA-based SDC2 Methylation Test: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genomictree, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyung Hee University Hospital at Gangdong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study of colorectal cancer screening using stool DNA-based SDC2 methylation test
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2020</start_date>
  <completion_date type="Anticipated">March 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 9, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SDC2 methylation in stool DNA</measure>
    <time_frame>1 year</time_frame>
    <description>positive ratio of SDC2 methylation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sensitivity and specificity of EarlyTect</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1112</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colon Polyp</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Confirmed colorectal cancer under colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colon polyp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Confirmed colorectal polyp under colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Confirmed no cancer nor polyp under colonoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Earlytect Colon Cancer</intervention_name>
    <description>A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer</description>
    <arm_group_label>Colon polyp</arm_group_label>
    <arm_group_label>Colorectal cancer</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who agreed the clinical trial and signed informed consent

          -  High risk patient for colorectal cancer (family history of colorectal cancer, history
             of adenomatous polyp excision, inflammatory bowel disease &gt; 15 years, or history of
             hereditary colorectal cancer)

          -  Patient who scheduled to receive colonoscopy

          -  Stool &gt; 20g before bowel preparation for colonoscopy

        Exclusion Criteria:

          -  No high risk patient under 60 years

          -  History of colorectal cancer

          -  Stool &lt; 20g or sample after bowel preparation

          -  Diarrhea or liquid stool which cannot be evaluated

          -  Patient who is judged as not suitable for clinical trial including a psychiatric
             disorder by a physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suk-Hwan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee University Hospital at Gangdong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang Woo Kim, MD, PhD</last_name>
    <phone>8224406222</phone>
    <email>kcwgkim@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Byung Soh Min</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byung Soh Min, MD, PhD</last_name>
      <email>bsmin@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suk-Hwan Lee</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Woo Kim, MD, PhD</last_name>
      <phone>024406222</phone>
      <email>kcwgkim@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </results_reference>
  <results_reference>
    <citation>Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006 Feb;6(2):107-16. Review.</citation>
    <PMID>16491070</PMID>
  </results_reference>
  <results_reference>
    <citation>Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer. 2005 Mar;5(3):223-31. Review.</citation>
    <PMID>15719030</PMID>
  </results_reference>
  <results_reference>
    <citation>Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003 Apr;3(4):253-66. Review.</citation>
    <PMID>12671664</PMID>
  </results_reference>
  <results_reference>
    <citation>Oh T, Kim N, Moon Y, Kim MS, Hoehn BD, Park CH, Kim TS, Kim NK, Chung HC, An S. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn. 2013 Jul;15(4):498-507. doi: 10.1016/j.jmoldx.2013.03.004. Epub 2013 Jun 7.</citation>
    <PMID>23747112</PMID>
  </results_reference>
  <results_reference>
    <citation>Xue M, Lai SC, Xu ZP, Wang LJ. Noninvasive DNA methylation biomarkers in colorectal cancer: A systematic review. J Dig Dis. 2015 Dec;16(12):699-712. doi: 10.1111/1751-2980.12299. Review.</citation>
    <PMID>26565661</PMID>
  </results_reference>
  <results_reference>
    <citation>Mansour H. Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection. Front Genet. 2014 Aug 27;5:182. doi: 10.3389/fgene.2014.00182. eCollection 2014. Review.</citation>
    <PMID>25221563</PMID>
  </results_reference>
  <results_reference>
    <citation>Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, Han YD, Chung HC, Kim NK, An S. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenetics. 2017 Dec 4;9:126. doi: 10.1186/s13148-017-0426-3. eCollection 2017.</citation>
    <PMID>29225717</PMID>
  </results_reference>
  <results_reference>
    <citation>Han YD, Oh TJ, Chung TH, Jang HW, Kim YN, An S, Kim NK. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenetics. 2019 Mar 15;11(1):51. doi: 10.1186/s13148-019-0642-0.</citation>
    <PMID>30876480</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyung Hee University Hospital at Gangdong</investigator_affiliation>
    <investigator_full_name>Suk-Hwan Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

